Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Yafit, Segman"'
Autor:
Tal Brosh-Nissimov, Nir Ma'aravi, Daniel Leshin-Carmel, Yonatan Edel, Sharon Ben Barouch, Yafit Segman, Amos Cahan, Erez Barenboim
Publikováno v:
Journal of Microbiology, Immunology and Infection, Vol 57, Iss 1, Pp 189-194 (2024)
We present a retrospective study on the treatment outcomes of severely immunocompromised patients with persistent COVID-19. The study analyzed data from 14 patients who received a combination of tixegavimab/cilgavimab and antiviral medications. Respo
Externí odkaz:
https://doaj.org/article/48f049c1ea3b40f5bff0e642493ab416
Autor:
Tali Shafat, Daniel Grupel, Tzvika Porges, Ran Abuhasira, Ana Belkin, Ofir Deri, Yonatan Oster, Shadi Zahran, Ehud Horwitz, Netanel A. Horowitz, Hazim Khatib, Marjorie Vieira Batista, Anita Cassoli Cortez, Tal Brosh‐Nissimov, Yafit Segman, Linor Ishay, Regev Cohen, Alaa Atamna, Amy Spallone, Roy F. Chemaly, Juan Carlos Ramos‐Ramos, Michal Chowers, Evgeny Rogozin, Noga Carmi Oren, Şiran Keske, Orit Wolfovitz Barchad, Lior Nesher, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV)
Publikováno v:
Cancer Medicine, Vol 13, Iss 3, Pp n/a-n/a (2024)
Abstract Objectives Hematological malignancy (HM) patients treated with anti‐CD20 monoclonal antibodies are at higher risk for severe COVID‐19. A previous single‐center study showed worse outcomes in patients treated with obinutuzumab compared
Externí odkaz:
https://doaj.org/article/113128f89fa94947817890d9ed48aae7
Autor:
Roi Gat, Miri Neeman, Shai Levi, Mor Levi, Nili Eilati, Yotam Bronstein, Tamir Shragai, Tsipora Neuman, Yafit Segman, Roy Vitkon, Moshe Mittelman, Irit Avivi, Yakir Moshe
Publikováno v:
HemaSphere, Vol 7, p e4811210 (2023)
Externí odkaz:
https://doaj.org/article/2d6ebc19a67847c1b107f6f5ad7269da
Autor:
Yakir Moshe, Shai Levi, Miri Neeman, Roi Gat, Mor Levi, Nili Eilati, Tamir Shragai, May Basood, Yafit Segman, Yaeli Baron, Efrat Luttwak, Tsipora Neuman, Roy Vitkon, Moshe Mittelman, Irit Avivi
Publikováno v:
HemaSphere, Vol 7, p e75498e6 (2023)
Externí odkaz:
https://doaj.org/article/ab4d16c1f22643a98c1d82c0ee9c63b8
Autor:
Efrat Luttwak, Yafit Segman, May Saban, Odit Gutwein, Irit Avivi, Chava Perry, Alina Filiavich, Nadav Sarid
Publikováno v:
Journal of Medical Screening. 29:255-259
Objective To determine the rate of lymphoproliferative disease (LPD) in women undergoing routine breast cancer screening (BCS). BCS can reveal pathologies other than carcinoma that involve the breast and lymph tissue. The few studies that have descri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::564714d48a6fa0fbc7f20d51d1495624
https://doi.org/10.1177/09691413221109988
https://doi.org/10.1177/09691413221109988
Autor:
Tal Brosh-Nissimov, Nir Ma’aravi, Daniel Leshin-Carmel, Yonatan Edel, Sharon Ben Barouch, Yafit Segman, Amos Cahan, Erez Barenboim
BackgroundLittle data exists to guide the treatment of persistent COVID-19 in immunocompromised patients. We have employed a unique protocol combining tixegavimab/cilgavimab, and short-term combination antivirals including remdesivir.MethodsA retrosp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::508cbe11aacd3f2ad5c2c649e916a4da
https://doi.org/10.1101/2023.04.07.23288144
https://doi.org/10.1101/2023.04.07.23288144
Autor:
Adrian, Duek, Emmanuel, Lellouche, Sharon, Ben Baruch, Reut, Mashiach, Yafit, Segman, Gabriel, Bryk, Merav, Leiba
Publikováno v:
The Israel Medical Association journal : IMAJ. 24(10)
Multiple myeloma (MM) accounts for approximately 10% of hematological malignancies. The monoclonal immunoglobulin G kappa (IgG-κ) daratumumab can bind to CD38 on MM cells and be detected in serum immunofixation (IF), causing pitfalls in M-protein qu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::df8ec4fbe0f15f6b5bdb14ec0ca28e53
https://pubmed.ncbi.nlm.nih.gov/36309856
https://pubmed.ncbi.nlm.nih.gov/36309856
Publikováno v:
The Israel Medical Association journal : IMAJ. 23(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::284318fb70dd341fd027c7fb486ee80a
https://pubmed.ncbi.nlm.nih.gov/34251134
https://pubmed.ncbi.nlm.nih.gov/34251134
Autor:
Noam Benyamini, Miri Zektser, Odit Gutwein, Nadav Sarid, Gilad Itchaki, Anatoly Nemets, Uri Abadi, Nagib Dally, Shimrit Harlev, Kalman Filanovsky, Elena Ribakovsky, Merav Leiba, Netanel A Horwitz, Ron Ram, Chava Perry, Ronit Gurion, Abraham Avigdor, Orit Sofer, Irit Avivi, Yafit Segman, Neta Goldschmidt, Tamar Tadmor, Yair Herishanu, Vladimir Vainstein, Yair Goldhecht
Publikováno v:
Leukemialymphoma. 62(1)
The efficacy of polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma outside clinical study are undetermined. This retrospective study examined the efficacy and safety of polatuzumab vedotin administered in real life settings. For
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aed7fd719426bd3d6751ddebcaf37b3a
https://pubmed.ncbi.nlm.nih.gov/32981410
https://pubmed.ncbi.nlm.nih.gov/32981410
Autor:
Shimrit Ringelstein Harlev, Najib Dally, Chava Perry, Vladimir Vainstein, Neta Goldschmidt, Orit Sofer, Nadav Sarid, Noam Benyamini, Ron Ram, Uri Abadi, Elena Ribakovsky, Merav Leiba, Yair Herishanu, Odit Gutwein, Anatoly Nemets, Irit Avivi, Abraham Avigdor, Yafit Segman, Kalman Filanovsky
Publikováno v:
Blood. 134:5321-5321
Introduction The therapeutic options for diffuse large cell B cell lymphoma (DLBCL) patients (pts) that fail to respond/relapse after≥2 treatment regimens are limited. The SCHOLAR-1 study reported an overall response/ complete remission (ORR/CR) ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::911dd0b54075a0e3621e3e89cd54e63e
https://doi.org/10.1182/blood-2019-124164
https://doi.org/10.1182/blood-2019-124164